Answers are grounded in this paper and cite their sources.
Evidence supporting daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) in transplant-eligible patients aged 65–69 years with newly diagnosed multiple myeloma (NDMM) remains limited, particularly among Asian patients. Furthermore, the efficacy of six cycles of D-VRd induction before autologous stem cell transplantation (ASCT) has not been prospectively evaluated. In this multicenter, single-arm, phase II study, 26 transplant-eligible patients aged 65–69 years with NDMM received six cycles of D-VRd induction followed by ASCT. Maintenance therapy consisted of daratumumab plus lenalidomide for 12 months, followed by daratumumab monotherapy for another 12 months. The primary endpoint was the rate of very good partial response (VGPR) or better after ASCT. All patients completed induction, and 25 (96.2%) underwent ASCT. The VGPR or better rate after ASCT was 96.2%. The MRD-negative rate was 92.3%, and 65.4% achieved sustained MRD negativity for 12 months. After a median follow-up of 42.5 months, 3-year progression-free and overall survival rates were 76.9% and 88.5%, respectively. Grade ≥ 3 neutropenia was the most common adverse event, while dose intensity was generally maintained. Six cycles of D-VRd induction followed by ASCT and fixed-duration daratumumab-based maintenance achieved deep and durable responses with manageable toxicity in fit, transplant-eligible patients aged 65–69 years.
No takes yet. Share an insight, caveat, or question.
Kım et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: